TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized~* Must be first admission of COVID-19, not re-admission~* Primary reason for hospitalization or prolonged hospitalization is because of acute COVID-19 diagnosis~* Adults 18 years of age or greater~* Laboratory-proven COVID-19 within 14 days prior to hospital admission~Exclusion Criteria:~* Hypotension (SAP \< 100 mmHg or DAP \< 50 mmHg or MAP \< 65 mmHg)~* Hyperkalemia (\> 5.5 mmol/l)~* Acute kidney injury (urine output \< 0.5 ml/kg/hr and new creatinine \> 200 mmol/l, or increase \> 100 mmol/l, or GFR \< 30 ml/min)~* Use of aliskiren in patients with diabetes mellitus (type 1 or type 2) or moderate-severe renal impairment (GFR less than 60mL/min)~* Use of ARB/ACEi within 7 days of presentation~* Pregnant or breastfeeding~* Have a known allergy to ARBs or any component of the drug product~* Have written legal document to withhold life-sustaining (patients not wishing to receive Cardiopulmonary Resuscitation (CPR) can participate if other medical treatments will be given)~* Have signed a Do No Resuscitate (DNR) Form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan) (Type: EXPERIMENTAL): Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
- Usual Care Control (Type: NO_INTERVENTION): Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVAD (HVAD, Heartware Inc., Framingham, MA, USA) implantation more than one month ago~* Stable renal function (clinical judgement)~* Age 18 years or older~* Ability to give informed consent~Exclusion Criteria:~* Severe chronic renal impairment (CL\<30)~* History of significant thromboembolic events~* Significant bleeding disorder~* HIV or Hepatitis C infection~* Heparin induced thrombocytopenia~* Known hypersensitivity to Dabigatran or Phenprocoumon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study medication (Type: EXPERIMENTAL): Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate \>80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
- control group (Type: ACTIVE_COMPARATOR): Phenprocoumon dosage according to INR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Comparing Two Established Gastrointestinal Suture Techniques - One-layer-continuous Versus Double-layer-continuous Suture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years old,~* planned for elective surgery~* at least one hand-sutured ileo-colonic or colo-colonic anastomosis~Exclusion Criteria:~* ASA-Score \> 3,~* missing written consent of the informed patient~* no existing choice between suture-techniques according to the surgeon~* patient not able to cooperate/non-compliance~* rectal anastomoses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Layer-Suture (Type: EXPERIMENTAL): Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
- Single-layer suture (Type: ACTIVE_COMPARATOR): Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NCI UNC Project ESCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* All suspected ESCC cases will be eligible for enrollment.~* All KCH and St Gabriel s patients greater than or eqaul to 18 years of age who are residents of the Central Region of Malawi and are diagnosed with histology-confirmed ESCC will be invited to participate as cases in the study.~EXCLUSION CRITERIA:~* Patients \<18 years old~* Those living outside the Central Region, those who are medically unable to complete the study procedures (including questionnaire, biosample collection or endoscopy), and those who are unable to understand the study procedures or give informed consent.~While we do expect to see younger people with ESCC in Malawi (as we have seen in Kenya), cases under the age of 18 are rare: the field team would expect to see one or two a year. This estimate is in line with the cancer registry data from Malawi. Therefore, we will not enroll subjects younger than 18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Controls (Type: None): Controls
- ESCC Cases (Type: None): ESCC Cases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Loop Duodenal Switch: Outcomes at One Year

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject must be 19-70 years of age at the time of enrollment.~2. The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent.~3. The subject is under consideration for surgery for obesity or metabolic disease and elects to undergo a primary loop duodenal switch procedure or as a conversion procedure for failed, sustained weight loss after a sleeve gastrectomy or laparoscopic adjustable gastric band performed more than 12 months prior to time of evaluation.~4. The subject has a BMI of greater than or equal to 40 kg/m2 at time of surgical consultation.~Exclusion Criteria:~1. Subjects under 19 years of age or older than 70 years of age~2. Subject is not willing or able to participate in the study procedures and understand the informed consent.~3. The subject wishes to under a different bariatric procedure other than the loop duodenal switch.~4. The subject has a BMI of less than 40 kg/m2 at the time of surgical consultation.~5. Any female subject who is pregnant, or is actively breast-feeding~6. Any subject who is considered to be part of a vulnerable population (eg. prisoners or those with psychological concerns or those without sufficient mental capacity)~7. The procedure is an emergency procedure

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Loop DS Patients (Type: EXPERIMENTAL): Patients who receive a Loop DS procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: n-3 Enriched Nutrition Therapy and Postoperative Cognitive Dysfunction After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's undergoing elective cardiac procedure with extracorporeal circulation~* Age 65 or older~Exclusion Criteria:~* No informed written consent~* Redo operation~* Deep hypothermic cardiac arrest~* Operation including carotid endarterectomy~* Known allergy to n-3 fatty acids~* History of cerebrovascular disease~* Preoperative Mini mental score \< 23~* Long term neuroleptic medication

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): n-3 enriched nutrition
- 2 (Type: PLACEBO_COMPARATOR): isocaloric nutrition without n-3 supplement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TAK-994 in Adults With Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant with a diagnosis of Narcolepsy Type 1 (NT1) who has completed TAK-994-1501 Part B before enrollment (which will occur immediately following the final TAK-994-1501 assessments), and for whom the investigator has no clinical objection they be enrolled.~Exclusion Criteria:~1. Participant has a clinically significant moderate or severe ongoing AE related to the study drug from the prior study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active Drug Extension Period: TAK-994 30 mg (Type: EXPERIMENTAL): TAK-994 30 mg, twice daily (BID) tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Active Drug Extension Period: TAK-994 90 mg (Type: EXPERIMENTAL): TAK-994 90 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Active Drug Extension Period: TAK-994 180 mg (Type: EXPERIMENTAL): TAK-994 180 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Double-blind Randomized Withdrawal Period: TAK-994 30 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 30 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 30 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: TAK-994 90 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 90 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 90 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: TAK-994 180 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 180 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 180 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: Placebo (Type: PLACEBO_COMPARATOR): Following the Active Drug Extension Period participants meeting eligibility specification and received placebo-matching tablets for 4 weeks (from Day 57 to Day 84) in the Double-blind Randomized Withdrawal Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Elevated Serum HDL in Four Generations of a Nashville Family

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 26 living members of a family with HDL levels greater than 90mg/dl and several of whom will act as related age matched controls.~* The investigators will also identify individuals in a lipid core database with HDL's of greater than 90mg/dl who have normal or low LDL and triglyceride levels and determine if they have normal or low LDL and triglyceride levels and determine if they have family members (parents or siblings) who also have high HDL cholesterol.~Exclusion Criteria:~* Individuals who are not a member of the study family and individuals with high HDL's and elevated LDL and/or triglycerides.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Single family cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 ≤ 75 years of age~* Scheduled amputation at or above ankle joint, or a more proximal location but below or through the knee joint~* Documented severe lower extremity peripheral artery occlusive disease confirmed by clinical symptoms of critical limb ischemia and:~  * Frankly gangrenous tissue that merits amputation or~ * Angiographic evidence of occlusive peripheral artery disease within one month of screening~* Participant or legal representative signs informed consent~* Willingness to follow study instructions and follow-up visits~Exclusion Criteria:~* No informed consent is obtained~* If medically inappropriate to administer 250 mL colloidal solution daily for 4 consecutive days~* Uncontrolled hypertension (BP \> 160/90 mm Hg) despite 2 antihypertensive meds or BP \> 180/100 mm Hg if untreated~* Severe liver dysfunction defined by Total Bilirubin \> 3 mg/dL or twice the normal limit of serum AST or ALT~* Symptomatic CVD diagnosed w/ in last 6 months or known high grade carotid stenosis~* Any severe or unstable medical condition that might interfere w/ the evaluation of study medication~* Cardiogenic shock (cardiac index \< 2 L/min/m2, PCWP \> 18 mm Hg)~* Amputation above knee joint or below ankle joint~* Any amputation whereby primary skin closure not technically feasible~* Candidate for percutaneous or surgical revascularization~* Cardiac failure defined by a NY class III/IV or left ventricular ejection fraction \< 30%~* Life expectancy \< 60 days~* Systemic mastocytosis~* Previously demonstrated beef product allergy~* Myocardial infarction w/ in 30 days~* Participation in another trial w/ in last 30 days~* Woman who is pregnant or breastfeeding~* Amputation with known infection at site of skin closure~* Renal dysfunction requiring dialysis, or serum creatinine level 2.5 mg/dL~* Peripheral vascular occlusion from cardio arterial emboli~* Uncontrolled diabetes blood glucose ≥ 400 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Hemoglobin glutamer 250 - bovine
- 2 (Type: ACTIVE_COMPARATOR): 6% Hydroxyethylstarch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and Females aged between 18 and 75 years (included)~2. Pittsburgh Sleep Quality Index (PSQI) score ≥ 5~3. Diagnosed for breast, lung or colon-rectal cancer~4. Metastatic first chemotherapy line~5. Planned duration of chemotherapy treatment at least 63 days~6. Negative to pregnancy test~7. Patients able to swallow~Exclusion Criteria:~1. Known hypersensitivity reaction to Melatonin, Zinc or Magnesium or any components of the product~2. Known current drug or alcohol abuse.~3. Use of other investigational drug(s) within 30 days before study entry or during the study~4. Clinically significant findings on physical examination or presence of known clinically significant disease that would interfere with study evaluation~5. Patients treated with benzodiazepines, hypnotic, anticonvulsant, antipsychotic or antidepressant drugs in the two months before screening visit~6. Patients receiving or planned to receive warfarin~7. Chronic treatment with steroids with daily dose over 10 mg prednisone or equivalent product~8. Brain metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Somnage (Type: EXPERIMENTAL): Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration o.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Breakthrough Cancer Pain According to European Guidelines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of any ethnic origin of ≥ 18 years.~* Patients diagnosed with locally advanced or recurrent metastatic cancer (histologic or cytologic diagnosis), with BTcP, as assessed by the Investigator.~* Opioid-tolerant patients receiving doses of oral morphine equivalent daily doses (OMEDD) of at least 60 mg.~* Drugs for BTcP treatment, if any, must be used according to the relevant SmPC.~* Eastern Cooperative Oncology Group (ECOG) performance status with a score of 0, or 1, or 2.~* Patients with life expectancy \> 3 months.~* Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent.~Exclusion Criteria:~* Patients with previous or current history of a clinically significant neurological/psychiatric disorder and/or any substance abuse or dependence that, according to the Investigator's judgement, can impair the study end-points/results.~* Patients who have been taking antidepressants and/or drugs acting on pain and who take them on a regular basis during the observation period, can be enrolled.~* Any medical condition or situation complicating the collection of study data, as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GROUP A: Patients adherent to BTcP European Guidelines (Type: None): None
- GROUP B: Patients non Adherent to BTcP European Guidelines (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically demonstrated BCG-unresponsive, carcinoma in situ (CIS)-containing high-risk non-muscle-invasive bladder cancer (NMIBC) defined as CIS with or without papillary component~* Participants must have CIS to be eligible.~* Predominant histologic component (\> 50%) must be urothelial (transitional cell) carcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~Exclusion Criteria:~* Sign of locally advanced disease or metastatic bladder cancer~* Urothelial cancer (UC) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment~* Prior immuno-oncology therapy~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab monotherapy (Type: EXPERIMENTAL): None
- Nivolumab + BCG (Type: EXPERIMENTAL): None
- Nivolumab + BMS-986205 (Type: EXPERIMENTAL): None
- Nivolumab + BMS-986205 + BCG (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues